Does a high postmortem fentanyl concentration establish cause of death?

No, not standing alone. Postmortem redistribution can raise measured fentanyl well above in vivo levels — up to ninefold in one patch study — and depends heavily on whether cardiac or peripheral blood was drawn. A two-year county review found living impaired drivers at concentrations up to 303 ng/mL, overlapping the postmortem range almost entirely. Concentration is one input alongside tolerance, co-intoxicants, scene findings, and autopsy.

What exactly does Burrage require in a federal death-results case?

Where the distributed drug is not an independently sufficient cause of death, the twenty-year enhancement under § 841(b)(1) applies only if that drug's use was a but-for cause of the death or serious bodily injury. A jury instruction permitting conviction on a "contributing factor" theory is error. The death-results element must be submitted to the jury and proven beyond a reasonable doubt.

How can someone die after a naloxone reversal that visibly worked?

Naloxone's half-life in adults is roughly 30 to 80 minutes; fentanyl's elimination half-life is 3 to 7 hours. When the antagonist clears first, respiratory depression can recur — renarcotization. Standard guidance is to monitor a responder for 6 to 12 hours for exactly this reason, and repeat naloxone dosing is commonly required. Whether that observation happened is often the whole standard-of-care question.

Does naloxone reverse xylazine or medetomidine?

No. Both are alpha-2 adrenergic agonists, not opioids, and NIDA states plainly that naloxone and nalmefene do not reverse xylazine's effects. Naloxone is still indicated because these adulterants almost always accompany fentanyl. Clinically this changes the picture; forensically it changes both causation analysis and any intent analysis premised on what the defendant knew was in the product.

Which expert do I need — a medical toxicologist, a forensic toxicologist, or a chemist?

A medical toxicologist is a physician who addresses clinical causation, tolerance, treatment, and standard of care. A forensic toxicologist is a laboratory scientist who addresses analytical methodology, chain of custody, and specimen interpretation. A pharmaceutical or synthetic chemist addresses the molecule, formulation, synthesis route, and countermeasure science. Complex fentanyl matters frequently require two of the three, and the pairing should be deliberate.

Will routine toxicology testing catch the newer adulterants?

Frequently not. Common five-panel urine screens do not detect xylazine or medetomidine, and immunoassays used for conventional opioids are largely ineffective for most nitazenes; widely used fentanyl test strips do not detect nitazenes either. Confirmatory LC-MS/MS with an appropriate target panel is required. A negative screen is evidence about the assay's scope before it is evidence about the decedent.

The Synthetic Opioid Project | Fentanyl Pharmacology, Toxicology & Causation

Eight questions that decide synthetic opioid matters, answered from the primary literature. Every assertion carries a numbered citation to the source underneath it.

Why fentanyl kills

Fentanyl is a mu-opioid receptor agonist approximately 100 times more potent than morphine as an analgesic, with rapid onset and short duration, and it crosses the blood-brain barrier quickly. NIDA states that as little as 2 mg can be fatal. Death is respiratory. Opioid-induced respiratory depression is compounded, in some exposures, by skeletal muscle rigidity that stiffens the chest wall — what one review calls a "double whammy of a depressed respiratory drive and a mechanical restriction to breathing." Because the fentanyls are highly lipid-soluble, overdose deaths have been described occurring within five minutes, against more than thirty for heroin.^{[1, 2, 3, 4]}

The reversal myth: renarcotization

Naloxone displaces fentanyl from the receptor, but it does not stay there. Naloxone's half-life in adults runs roughly 30 to 80 minutes; fentanyl's elimination half-life is 3 to 7 hours. When the antagonist clears before the agonist, respiratory depression can return — renarcotization. Clinical reference guidance instructs that patients who respond to naloxone be monitored 6 to 12 hours precisely because some opioids have a much longer half-life than the antidote, and notes that repeated doses are commonly required. Fentanyl respiratory depression is documented as harder to reverse than heroin's, often needing multiple or higher doses. A successful reversal is where the standard-of-care inquiry begins, not where it ends.^{[2, 3, 4, 5]}

The adulteration era: what naloxone cannot reverse

Xylazine is a veterinary alpha-2 adrenergic agonist, not an opioid. NIDA is explicit that naloxone and nalmefene do not reverse xylazine's effects. CDC surveillance found the monthly share of illicitly-manufactured-fentanyl deaths with xylazine detected rose 276 percent, from 2.9 percent in January 2019 to 10.9 percent in June 2022. Medetomidine, a substantially more potent alpha-2 agonist, followed: it was detected in 72 percent of illegal opioid samples tested in Philadelphia in late 2024, and 165 patients across three health systems were hospitalized with a severe withdrawal syndrome, 91 percent of them requiring intensive care. Neither compound appears on standard five-panel urine screens.^{[7, 8, 9]}

Past fentanyl: the nitazenes

The supply keeps moving. Nitazenes — benzimidazole opioids with no accepted U.S. medical use — are now present in the American drug supply. Published comparisons place etonitazene at roughly 1,000 times the potency of morphine and 10 to 20 times that of fentanyl, with protonitazene about twice fentanyl's potency and metonitazene approximately equipotent. Because their chemistry differs from conventional opioids, immunoassays routinely used for opioid screening are largely ineffective for most nitazenes, and commonly used fentanyl test strips fail to detect them. Reversal has required high or repeated naloxone doses and, in some cases, continuous infusion. A drug nobody tested for is not a drug that was absent.^[10]

The number is not the cause

Postmortem redistribution alters drug concentrations after death. Lipophilic, highly protein-bound drugs with a large volume of distribution are most affected, and cardiac blood is unreliable next to peripheral blood — sampling site alone can produce an erroneous interpretation. For fentanyl specifically, postmortem concentrations have measured up to nine times higher than in vivo serum at the same dose, with no clear correlation between dose and concentration. A two-year county laboratory review found living impaired drivers with blood fentanyl from 0.5 to 303 ng/mL, against postmortem central blood of 0.6 to 636 ng/mL — ranges that overlap almost entirely. Tolerance widens the overlap further.^{[6, 11, 12, 13]}

But-for causation in federal death-results prosecutions

Under 21 U.S.C. § 841(b)(1), a defendant faces not less than twenty years when "death or serious bodily injury results from the use of such substance." In Burrage v. United States, 571 U.S. 204 (2014), Justice Scalia wrote for the Court that "at least where use of the drug distributed by the defendant is not an independently sufficient cause" of death or serious bodily injury, the enhancement does not apply "unless such use is a but-for cause of the death or injury." A contributing-factor instruction is error. The syllabus confirms, citing Alleyne, that the element goes to the jury beyond a reasonable doubt.^{[14, 15, 16, 17]}

Drug-induced homicide is a different animal

Thirty-one states and the District of Columbia had drug-induced homicide laws as of May 1, 2024 — a 33 percent increase over the 24 states in 2018 — according to the Center for Public Health Law Research at Temple University Beasley School of Law, which tracks these statutes across all fifty states, D.C., and federal law. They are not uniform. Some are standalone offenses, some operate through felony-murder theories, and four states — Arizona, Colorado, Florida, and Oklahoma — authorize a death sentence. Mens rea, causation standards, and available defenses differ jurisdiction to jurisdiction, and none of them is automatically bound by the federal but-for rule.^{[19, 20]}

What Rule 702 now demands of the expert

Since the December 1, 2023 amendment, Federal Rule of Evidence 702 requires the proponent to demonstrate to the court that it is "more likely than not" that each reliability condition is satisfied, and expressly requires that "the expert's opinion reflects a reliable application of the principles and methods to the facts of the case." In synthetic-opioid litigation that lands squarely on overstatement. An expert who converts one postmortem concentration into a cause-of-death conclusion, or a population-level lethal-dose figure into an individualized opinion about a tolerant decedent, is asserting more than the underlying method can carry.^[18]

What the science actually says about fentanyl

The mortality curve is bending down. The litigation curve is not.

What the record shows

What the science actually says

Why fentanyl kills

The reversal myth: renarcotization

The adulteration era: what naloxone cannot reverse

Past fentanyl: the nitazenes

The number is not the cause

But-for causation in federal death-results prosecutions

Drug-induced homicide is a different animal

What Rule 702 now demands of the expert

Matters that turn on this science

What to require of an expert in these matters

A physician who treats the poisoning. A chemist who works on the molecule.

Related expert witness specialties

Published, and in preparation

How Fentanyl Kills, Step by Step

The Number Is Not the Cause: Reading a Postmortem Fentanyl Report

Burrage, a Decade On: What But-For Causation Still Requires

After Xylazine: Medetomidine, Nitazenes, and the Tests That Miss Them

Answers, with the citation attached